Investigation of pulmonary hypertension in patients receiving tyrosine kinase inhibitors

Investigation of pulmonary hypertension in patients receiving tyrosine kinase inhibitors - TKI-induced PH

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016857

Enrollment

100

Registered

2015-03-20

Start date

2015-03-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic myelogenous leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia

Interventions

Tyrosine kinase inhibitor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients under treatment with TKI at the institutions participating this investigation.

Exclusion criteria

Exclusion criteria: Unable to obtain the consent.

Design outcomes

Primary

Measure	Time frame
Frequency of tyrosine kinase inhibitor induced pulmonary hypertension.	—

Secondary

Measure	Time frame
Risk factors associated with tyrosine kinase inhibitor induced pulmonary hypertension.	—

Countries

Japan

Contacts

Public ContactToshihiro Miyamoto

Kyushu University Hospital Department of medicine and biosystemic science

toshmiya@intmed1.med.kyushu-u.ac.jp092-642-5230

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026